Anesta Corp., a Salt Lake-based pharmaceutical firm, reported a net loss for the third quarter of $3,469,760, or 36 cents a share, compared to $2,010,417, or 21 cents a share for the same quarter last year.
The increase in net loss resulted from lower revenues and from planned market preparation activities for Actiq in collaboration with Abbott Laboratories. Anesta's New Drug Application for Actiq is in review at the FDA. Revenue for the quarter was $51,714, compared to $398,577 for the same period a year ago.For the nine months ended September 30, 1997, the company's net loss was $8,729,003, or 92 cents a share, compared to $5,944,117, or 73 cents a share, for the first nine months of 1996. Revenue was $112,668 vs. $1,199,986 a year ago. Revenue for the quarter was entirely product sales.